Celldex Therapeutics presented long-term Phase 2 results for barzolvolimab at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul this week, reporting that improvements in angioedema were sustained seven months after the final dose — through Week 76 of follow-up — in patients with chronic spontaneous urticaria (CSU) who had failed antihistamine therapy. The data, delivered in a flash-talk session, reinforce the compound's potential as a disease-modifying intervention rather than a symptomatic stopgap.
Barzolvolimab is a monoclonal antibody targeting KIT (CD117), the receptor expressed on mast cells and their progenitors. By selectively depleting mast cells, the drug interrupts the upstream driver of urticarial flares and angioedema episodes rather than blocking downstream histamine signaling. The Phase 2 cohort comprised antihistamine-refractory CSU patients — a population with high unmet need — and the durable off-treatment response observed at Week 76 suggests a prolonged biological reset of mast-cell burden, a clinical endpoint that distinguishes the mechanism from existing biologics such as anti-IgE therapy. Celldex has not published peer-reviewed data from this specific long-term follow-up cohort at the time of the conference presentation.
While barzolvolimab is a pharmaceutical asset rather than a finished formulation or dietary supplement, the mast-cell biology it illuminates is directly relevant to the functional-foods and nutraceutical channel. Mast-cell stabilization is an active research area for ingredients including quercetin, palmitoylethanolamide (PEA), and certain standardized plant extracts that carry structure-function claims around immune comfort and histamine balance. Operators developing products for allergy-adjacent wellness — a segment growing alongside consumer demand for proactive immune support — will find the clinical framing of mast-cell depletion as a disease-modification strategy useful context for positioning ingredient stacks to retail buyers and healthcare practitioners. Peer-reviewed confirmation of the Week 76 data would strengthen the mechanistic narrative across both pharma and nutraceutical categories.
Celldex has initiated Phase 3 trials of barzolvolimab in CSU, and positive outcomes would likely accelerate regulatory and formulary conversations that in turn raise consumer awareness of mast-cell biology as a target. For nutraceutical brands, that awareness cycle historically translates into retailer and practitioner interest in ingredient solutions operating in the same mechanistic space — even when those ingredients work through complementary rather than identical pathways. Brands active in the immune-health supplement category or building science-backed stacks for histamine and skin-comfort claims should monitor the Phase 3 readout timeline closely.
From a supply-chain and co-manufacturing perspective, the broader mast-cell wellness space remains underdeveloped relative to categories like gut health or cognitive performance. Ingredient suppliers with GRAS-affirmed or QPS-status actives in the mast-cell stabilization space may find the EAACI data — and the Phase 3 momentum it signals — a useful hook for positioning conversations with functional-beverage and supplement formulators looking to differentiate in the crowded immune-support segment.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.